BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE

Jean-Frédéric Colombel  ¹     Walter Reinisch  ²     Stefan Schreiber  ³     Silvio Danese  ⁴     Ken Sugimoto  ⁵     Maria T. Abreu  ⁶     Naomi Martin  ⁷     Kristina Kligys     Valerie Pivorunas     Alexandra Song     Javier Zambrano     Yafei Zhang     Remo Panaccione  ^8    
1 Icahn School of Medicine at Mount Sinai, USA, United States
² Medical University of Vienna, Wien, Austria
³ University Hospital Schleswig-Holstein, Kiel, Germany
⁴ Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy
⁵ Hamamatsu University School of Medicine, Hamamatsu, Japan
⁶ University of Miami, Miller School of Medicine, Miami, United States
⁷ AbbVie Inc., North Chicago, United States
⁸ University of Calgary, Calgary, Canada

Session
Response prediction in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)